The First Affiliated Hospital with Nanjing Medical University: Breast Neoplasms trials

The registry lists 51 Breast Neoplasms studies with The First Affiliated Hospital with Nanjing Medical University as lead sponsor. 33 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 22Phase 4 1No phase 27(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• CT-AI Breast Cancer Opportunistic Screening Health Examination StudyNot yet recruitingNCT07809698Not applicable
• Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSFNot yet recruitingNCT07806084
• Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized TrialRecruitingNCT07698366Not applicable
• Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast CancerNot yet recruitingNCT07677956
• Prospective Cohort Study of Local Recurrence After Radical Breast Cancer ResectionNot yet recruitingNCT07668362
• Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHPNot yet recruitingNCT07589699Phase 4
• Comparison of Breast Sensory Recovery Between Conventional and Endoscopic Nipple-Sparing Mastectomy Combined With Prepectoral Implant ReconstructionNot yet recruitingNCT07372339Not applicable
• Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant TherapyRecruitingNCT07113613Phase 2
• Efficacy of Auricular Acupuncture Therapy in the Prevention of CIPN in Breast CancerRecruitingNCT07092111Not applicable
• RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07065435Phase 2
• Hypofractionated Radiation Fractionation in Breast Cancer Patients with Implant-Based ReconstructionRecruitingNCT06830083Not applicable
• To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)RecruitingNCT06817954Not applicable
• The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical StudyRecruitingNCT06770296Phase 1
• To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection Combined With Immediate Breast Reconstruction in Breast CancerNot yet recruitingNCT06706726Not applicable
• Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingNCT06656624Phase 2
• To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast CancerNot yet recruitingNCT06561646Not applicable
• Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer PatientsRecruitingNCT06479460
• To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNot yet recruitingNCT06470633Phase 2
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast CancerRecruitingNCT06341894Phase 2
• Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast CancerRecruitingNCT06288620Not applicable
• The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical StudyRecruitingNCT06254690Phase 2
• Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive ImpairmentNot yet recruitingNCT06234150Not applicable
• Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP TherapyRecruitingNCT06125834Phase 2
• A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast CancerRecruitingNCT06001086Phase 2
• Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer PatientsRecruitingNCT05974449Phase 2
• Omission of ALND in Breast Cancer Patients With Axillary pCRRecruitingNCT05939830Not applicable
• Omission of SLNB in CN0 Early Breast CancerRecruitingNCT05935150Not applicable
• Pyrotinib in Women With High-risk in Early Stage Breast CancerRecruitingNCT05834764Phase 2
• Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingNCT05834582Phase 2
• Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast CancerRecruitingNCT05823623Phase 2
• Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2
• Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective StudyRecruitingNCT05444647
• Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast CancerNot yet recruitingNCT05430347Phase 2
• Behavior Change Wheel-Based Music Listening for Chemotherapy-Related Cognitive Impairment in Breast Cancer PatientsCompletedNCT07641114Not applicable
• Real-World Treatment of ADC-Resistant HER2-Low Advanced Breast CancerCompletedNCT07587983
• Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world StudyCompletedNCT07108595
• Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast CancerActive, not recruitingNCT06926088
• A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast CancerCompletedNCT06168227
• Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast CancerStatus unknownNCT05808582Phase 2
• Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast CancerStatus unknownNCT05764941
• Precision Breast Conserving Surgery With Guidance.CompletedNCT05708664Not applicable
• To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerStatus unknownNCT05491694Phase 2
• Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world StudyStatus unknownNCT05231863
• Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast CancerStatus unknownNCT04899128
• Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast CancerCompletedNCT04805736Phase 2
• Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerStatus unknownNCT04717531Phase 2
• Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerStatus unknownNCT04624711Phase 2
• Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsStatus unknownNCT04502680Phase 2
• Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for CN+ Breast CancerCompletedNCT04482803Not applicable
• Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer ChemotherapyCompletedNCT04477616Phase 2
• This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of TreatmentStatus unknownNCT03650738Phase 2